HER-2 L869R
|
HER2 Positive Breast Cancer
|
HER-2 L869R
|
HER2 Positive Breast Cancer
|
neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
|
neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical
|
HER-2 L869R
|
HER2 Positive Breast Cancer
|
HER-2 L869R
|
HER2 Positive Breast Cancer
|
neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
HER-2 L869R
|
Breast Cancer
|
HER-2 L869R
|
Breast Cancer
|
ado-trastuzumab emtansine Resistant: D – Preclinical
|
ado-trastuzumab emtansine Resistant: D – Preclinical
|